Concepedia

Author

Marina Kremyanskaya

Icahn School of Medicine at Mount SinaiORCID

Also Known As

Kremyanskaya, M., M. Kremyanskaya, M., Kremyanskaya, Marina Kremyanskaya, R Hoffman, Schuh, Andre C

284

Publications

2.2K

Citations

26

H-Index

27

Concepts

All Affiliations

Icahn School of Medicine at Mount SinaiMemorial Sloan Kettering Cancer CenterThe University of Texas MD Anderson Cancer CenterMayo Clinic in ArizonaMays Cancer Center at UT Health San Antonio
MK

About

Marina Kremyanskaya is an author at Icahn School of Medicine at Mount Sinai specializing in medicine, hematology, and oncology.

Top Concepts

#ConceptH-IndexPublicationsCitations

1

Medicine

7

7

157

2

Health Sciences

3

3

105

3

Natural Sciences

1

1

14

4

Cell Biology

1

1

14

5

Immunology

1

1

68

Marina Kremyanskaya

×

47

Publications

1.5K

Citations

23

H-Index

YearCitations

Pegylated interferon alfa-2a for polycythemia vera or essential thrombocythemia resistant or intolerant to hydroxyurea

Abdulraheem Yacoub, John Mascarenhas, Heidi Kosiorek,

Blood

2019

165

MANIFEST: Pelabresib in Combination With Ruxolitinib for Janus Kinase Inhibitor Treatment-Naïve Myelofibrosis

John Mascarenhas, Marina Kremyanskaya, Andrea Patriarca,

Journal of Clinical Oncology

2023

75

Update on a Phase 1/2 First-in-Human Study of the Menin-KMT2A (MLL) Inhibitor Ziftomenib (KO-539) in Patients with Relapsed or Refractory Acute Myeloid Leukemia

Harry P. Erba, Amir T. Fathi, Ghayas C. Issa,

Blood

2022

68

Phase 2 study of ruxolitinib and decitabine in patients with myeloproliferative neoplasm in accelerated and blast phase

John Mascarenhas, Raajit K. Rampal, Heidi Kosiorek,

Blood Advances

2020

67

A Phase 2 Study of Luspatercept in Patients with Myelofibrosis-Associated Anemia

Aaron T. Gerds, Alessandro M. Vannucchi, Francesco Passamonti,

Blood

2019

66

Combination treatment in vitro with Nutlin, a small-molecule antagonist of MDM2, and pegylated interferon-α 2a specifically targets JAK2V617F-positive polycythemia vera cells

Min Lü, Xiaoli Wang, Yan Li,

Blood

2012

65

Safety and efficacy of combined ruxolitinib and decitabine in accelerated and blast-phase myeloproliferative neoplasms

Raajit K. Rampal, John Mascarenhas, Heidi Kosiorek,

Blood Advances

2018

61

Safety and Efficacy: Clinical Experience of Venetoclax in Combination With Hypomethylating Agents in Both Newly Diagnosed and Relapsed/Refractory Advanced Myeloid Malignancies

Jonathan Feld, Douglas Tremblay, Mikaela Dougherty,

HemaSphere

2021

49

PRM-151 in Myelofibrosis: Efficacy and Safety in an Open Label Extension Study

Srđan Verstovšek, Robert P. Hasserjian, Olga Pozdnyakova,

Blood

2018

47

MANIFEST, a Phase 2 Study of CPI-0610, a Bromodomain and Extraterminal Domain Inhibitor (BETi), As Monotherapy or "Add-on" to Ruxolitinib, in Patients with Refractory or Intolerant Advanced Myelofibrosis

John Mascarenhas, Marina Kremyanskaya, Ronald Hoffman,

Blood

2019

45

Page 1